A Phase II Study of RO4929097 Gamma-Secretase Inhibitor in Metastatic Melanoma: SWOG 0933

BACKGROUND: Aberrant Notch activation confers a proliferative advantage onto many human tumors, including melanoma. This phase II trial assessed the antitumor activity of RO4929097, a gamma-secretase inhibitor of Notch signaling, on the progression-free and overall survival of patients with advanced...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer
Päätekijät: Lee, Sylvia M., Moon, James, Redman, Bruce G., Chidiac, Tarek, Flaherty, Lawrence E., Zha, Yuanyuan, Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Gajewski, Thomas F., Margolin, Kim A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304973/
https://ncbi.nlm.nih.gov/pubmed/25250858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29055
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia